Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)

Philipp Harter; Patricia Pautier; Els Van Nieuwenhuysen; Alexander Reuss; Andres Redondo; Kristina Lindemann; Christian Kurzeder; Edgar Petru; Florian Heitz; Jalid Sehouli; Nikolaus Degregorio; Pauline Wimberger; Alexander Burges; Nadin Cron; Jonathan Ledermann; Domenica Lorusso; Xavier Paoletti; Frederik Marme

doi:10.1136/ijgc-2020-001572

Citation Tools

other Versions

You are currently viewing an earlier version of this article (June 30, 2020).
View the most recent version of this article

Clinical trial

Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Harter P, Pautier P, Van Nieuwenhuysen E, et al

Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)

International Journal of Gynecologic Cancer Published Online First: 30 June 2020. doi: 10.1136/ijgc-2020-001572

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password